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Abstract
Antiphospholipid syndrome (APLS) is a rare syndrome mainly characterized by several hyper-coagulable
complications and therefore, implicated in the operated cardiac surgery patient. APLS comprises clinical features
such as arterial or venous thromboses, valve disease, coronary artery disease, intracardiac thrombus formation, pul-
monary hypertension and dilated cardiomyopathy. The most commonly affected valve is the mitral, followed by
the aortic and tricuspid valve. For APLS diagnosis essential is the detection of so-called antiphospholipid antibodies
(aPL) as anticardiolipin antibodies (aCL) or lupus anticoagulant (LA). Minor alterations in the anticoagulation, infec-
tion, and surgical stress may trigger widespread thrombosis. The incidence of thrombosis is highest during the fol-
lowing perioperative periods: preoperatively during the withdrawal of warfarin, postoperatively during the period of
hypercoagulability despite warfarin or heparin therapy, or postoperatively before adequate anticoagulation achieve-
ment. Cardiac valvular pathology includes irregular thickening of the valve leaflets due to deposition of immune
complexes that may lead to vegetations and valve dysfunction; a significant risk factor for stroke. Patients with
APLS are at increased risk for thrombosis and adequate anticoagulation is of vital importance during cardiopul-
monary bypass (CPB). A successful outcome requires multidisciplinary management in order to prevent thrombotic
or bleeding complications and to manage perioperative anticoagulation. More work and reporting on anticoagula-
tion management and adjuvant therapy in patients with APLS during extracorporeal circulation are necessary.
Introduction
Antiphospholipid syndrome (APLS) [1,2] comprises clini-
cal features such as arterial or venous thromboses and the
detection of so-called antiphospholipid antibodies (aPL) as
anticardiolipin antibodies (aCL) or lupus anticoagulant
(LA). APLS may be the most common acquired hypercoa-
gulable state, occurring in up to 2% of the general popula-
tion [3,4]. However, not all patients with these antibodies
will develop the antiphospholipid syndrome, as antipho-
spholpid antibodies have been found in about 5% of the
healthy population [5]. Patients with APLS have a signifi-
cant involvement of the cardiovascular system. Coronary
artery disease and valvular abnormalities constitute the
most frequent manifestations representing more than two-
thirds of cases [5]. Several studies have demonstrated that
hypercoagulability of APLS patients predisposes to high
rates of thromboembolic events as well as high rate of
restenosis of the coronaries and the grafts after percuta-
neous interventions or CABG respectively, causing signifi-
cant morbidity and mortality [6,7]. Especially, APLS
patients can develop vasculo-occlusive complications
before operation with the reversal of preoperative anti-
coagulation, intraoperatively due to inadequate anticoagu-
lation during bypass and postoperatively before the
achievement of adequate anticoagulation [8]. Therefore,
the management of APLS patient can be quite challenging
both for cardiologist and cardiac surgeon.
Etiology-Pathophysiology
Anticardiolipin (aCL) antibodies are a heterogeneous
family of auto-antibodies directed against protein-
phospholipid complexes [6]. It is now generally
accepted that there is a group of patients in whom
high titers of aCL antibodies, usually the IgG class, and
thrombotic features occur without clinical manifesta-
tions of systemic lupus erythematosus (SLE): primary
APLS [2,6]. Anticardiolipin antibodies can be also
observed in patients with SLE, or other autoimmune
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Moreover, it has been proved that the pathogenic anti-
bodies accountable for the APLS main symptoms are
not direct aPL against phospholipids itself; as produced
in infections (e.g. syphilis), neoplastic disorders or
induced by certain drugs (e.g. phenothiazines, quini-
dine) but rather indirect “aPL” directed against certain
phospholipid depending proteins [2,9]. The targets of
pathogenic antibodies in APLS are plasma or vascular
cell proteins. Specifically, the main target antigens
reported in patients with APLS include beta-2-glyco-
protein-1 (b2GPI), prothrombin and annexin V [2,10].
Other putative antigens are thrombin, protein C, pro-
tein S, thrombomodulin, tissue plasminogen activator,
kininogens (high or low molecular), prekallikrein, fac-
tor VII/VIIa, factor XI, factor XII, complement compo-
nent C4, heparan sulfate proteoglycan, heparin,
oxidised low-density lipoproteins [10,11]. The main
autoantigens are attracted to negatively charged phos-
pholipids (PL
(-)) exposed on the outer side of cell
membranes in great amounts only under special cir-
cumstances such as damage or apoptosis (e.g. endothe-
lial cell) or after activation (e.g. platelets) [2,12].
Several membrane receptors have been recognized as
signal transducers and after intracellular processing of
the signal, the expression of adhesion molecules as E-
selectin, vascular-cell-adhesion-molecule-1 (VCAM-1)
or intracellular adhesion-molecule-1 (ICAM-1) increase
the adhesion of immunocompetent cells further acti-
vating endothelial cells [2,13]. Furthermore, the
production of tissue factor or inhibition of tissue-
factor-pathway-inhibitor (TFPI) activates the extrinsic
coagulation pathway [2,14], while the simultaneous
decreased production of prostacyclin induces vasocon-
striction and platelet aggregation. The activation of
platelets results in the production of thromboxane A2
with further platelet activation and increased adhesion
to collagen [15]. On the other hand, the displacement
of tissue type plasminogen activator (t-PA) from
annexin II, an endothelial cell membrane receptor and
simultaneously enhancer to t-PA [16] could reduce the
plasmin activation leading in deceleration of fibrinoly-
sis [2]. The above potential activated pathways cause a
prothrombotic state in APLS (table 1).
Generally, the binding of aPL to platelet membrane
phospholipid-bound proteins may initiate platelet aggre-
gation and thrombosis. Thrombosis may comprise the
final common pathway of many processes, each based
on its own particular autoantibody profile [8,17]. Indeed,
in nearly 30% of patients with APLS, aPL antibodies
react with phospholipids on the surface of activated pla-
telets causing platelet adhension and thrombocytopenia.
As only activated platelets expose phospholipid, it is
usually thrombotic APLS patients who develop throm-
bocytopenia [18]. However, thrombocytopenia is not
protective against thrombosis. Several explanations exist
as to why increased aCL may contribute to increased
thrombotic risk, including platelet damage, interference
with antithrombin III activity, and inhibition of prekal-
likrein or protein C activation by thrombomodulin
[19,20]. In addition, thrombotic complications appear to
result from aPL-mediated displacement of annexin-V
from phospholipid surfaces [21]. This displacement of
annexin-V increases the quantity of coagulation factor
binding sites potentially leading to a procoagulant state
[22]. Because many individuals with high aPL antibody
titers remain asymptomatic, several studies have pro-
posed a 2-hit hypothesis. The presence of aPL antibo-
dies induces endothelial dysfunction (first hit) and
another condition (second hit) such as pregnancy infec-
tion, or vascular injury trigger thrombosis [8,23].
Clinical manifestations of APLS
Cardiac manifestations in APLS include valvular disease,
coronary artery disease, intracardiac thrombus forma-
tion, pulmonary hypertension and dilated cardiomyopa-
thy [5,8]. Cardiac valvular pathology includes irregular
thickening of the valve leaflets due to deposition of
immune complexes that may lead to vegetations and
valve dysfunction. These lesions are frequent and may
be a significant risk factor for stroke [8]. Noninfectious
and noninflammatory but rather thrombotic or fibrotic/
calcific lesions are found in patients with primary APLS
[2,24]. APLS is combined with SLE in about 40% of all
APLS patients and consequently heart valvular lesions
can also be caused by a SLE specific mechanism [24].
Non-autoimmunogenic reasons for heart valve failure in
Table 1 Pathways and mechanisms resulting in a
prothrombotic state in APLS
Pathway Mechanism
Activation of
endothelial cells:
expression of adhesion molecules or tissue
factor (2,13,14)
Activation of
thrombocytes:
induction of thromboxane A2, increased
adhension (15)
Activation of
coagulation cascade:
A. tissue factor production (activation of
extrinsic pathway: monocytes (14)
B. via thrombin activation (direct mechanism)
(2,10)
C. via cell activation (indirect mechanism) (2)
Inhibition of
anticoagulation:
A. inhibition of plasminogen/plasmin (2,16)
B. inhibition of t-PA by displacement from
annexin II (16)
C. inhibition of protein C by thrombomodulin
(2,11)
D. inhibition of protein S (11)
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monly affected valve is the mitral, followed by the aortic
and tricuspid valves; because the surface of the left-
sided valves is more vulnerable to micro injuries due to
stress, jet effect and turbulence [2,8]. Notably, the inci-
dence of arterial embolization is estimated to be 77% in
patients with APLS and simultaneous mitral valve dis-
ease [8,25]. Several studies have demonstrated a positive
correlation between the aCL titers and valvular heart
disease severity [5,7]. Most patients develop a mild form
of valvular regurgitation while 4-6% of patients progress
to severe valvular regurgitation necessitating replace-
ment surgeries [5,26]. The rather young age of the
patients and the most often necessary long-term antic-
oagulation for APLS seem to make a mechanical valve
the first choice if a replacement is needed but throm-
boembolic complications render a mechanical valve in
danger of dysfunction [2,27]. The advantage of a bio-
prosthesis is the independence of oral anticoagulation,
however valve failure due to excessive pannus and con-
secutive stenosis renders replacement inevitable after
some years [2,28]. Additionally, accelerated atherosclero-
sis increases the risk of coronary artery disease; the
etiology seems to be more related with inflammatory
and immunopathologic factors as compared with tradi-
tional Framingham cardiovascular risk factors [8,29].
The presence of intracardiac thrombus is a rare but
potentially a life-threatening manifestation of APLS.
Thrombus formation, a potential cause of pulmonary
and systemic emboli, may occur in any cardiac chamber
but most frequently on the right side [8]. Antiphospholi-
pid antibodies have been associated with various other
thrombogenic complications such as recurrent thrombo-
sis, thrombocytopenia and serious bleeding abnormal-
ities [30-32]. Of those patients with APLS who present
with thrombosis, 30 ± 55% will present with venous
thrombosis, especially of the lower limbs [18]. Repeat
episodes of thrombosis are often of the same type [33].
However, it is paradox that despite the well-documented
coexistence of autoantigens and its antibodies in blood
of APLS patients for long periods, thrombotic events
occur only sporadically. Eventually, it can be assumed
that thrombotic events occur much more often but only
in microvasculature or smaller vessels, resulting in dete-
rioration of organ function such as renal failure, cerebral
damages or impairment of the myocardial function by
multiple recurrent microthromboses or microemboli
[26]. Neurologic manifestations of APLS have been
reported to include recurrent cerebral infarcts, head-
aches, migraines and visual disturbances [34,35]. Other
manifestations of APLS include skin ulcers (pyoderma
gangrenosum- like or livedoid vasculitis) due to fibrin
deposition within the lumens of superficial dermal ves-
sels as well as diffuse alveolar haemorrhage [36]. Of
note, acute diffuse alveolar haemorrhage may be present
in fully anticoagulated patients that could be attributed
to a non-thrombotic pathogenesis in contrast to typical
alveolar haemorrhage. Catastrophic APLS (cAPLS) is an
acute condition with multiple vascular occlusions result-
ing in failure of several organs simultaneously or over a
short period of time (days to weeks) [2,37]. It can be
triggered by surgery, infection or changes in anticoagu-
lation therapy [3,4]. cAPLS presents a mortality of 50%
and can resemble syndromes such as heparin-induced
thrombocytopenia (HIT), disseminated intravascular
coagulation (DIC), systemic inflammatory response syn-
drome (SIRS), SLE vasculitis, thrombotic thrombocyto-
penic purpura (TTP) or sepsis [2].
Diagnosis
Diagnosis of APLS includes clinical criteria of thrombo-
sis and/or pregnancy morbidity and laboratory proof of
lupus anticoagulants and/or anticardiolipin antibodies in
medium or high titers on two or more occasions at least
twelve weeks apart [2,25]. aPL antibodies are a heteroge-
neous group and thus diagnosis requires more than one
test. The two main antibody groups are aCL antibodies
and LA; however patients with aCL antibodies are five
times more common than those with LA [18]. Results of
aCL assays are expressed as IgG and IgM phospholipids
units (GPL or MPL units) based on standard curves.
According to the updated classification criteria for APLS
[1] the diagnosis of APLS requires at least one of the
following clinical (vascular thrombosis or complications
of pregnancy) and one of the laboratory criteria.
Diagnostic (classification) criteria of APLS (1)
I. Clinical criteria
1. Vascular thrombosis Arterial, venous or small vessel
thrombosis in any tissue or organ, to be confirmed by
objective validated criteria (imaging studies or histo-
pathology). For histopathologic confirmation, thrombo-
sis should be present without significant evidence of
inflammation in the vessel wall.
2. Pregnancy morbidity -One or more unexplained
deaths of a morphologically normal fetus beyond the
10th week of gestation or
-One or more premature births of a morphologically
normal neonate before the 34th week of gestation
because of eclampsia or preeclampsia or placental
insufficiency.
-Three or more unexplained consecutive spontaneous
abortions before the 10th week of gestation.
II. Laboratory criteria
1. Lupus anticoagulants in plasma.
2. Anticardiolipin antibody of IgG and/or IgM isotype
in serum or plasma, present in medium or high titer
(i.e. >40 GPL or MPL).
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Laboratory tests: approaching potential
limitations
The definition of “APLS” requires the positive testing for
lupus anticoagulant, anti-cardiolipin or anti-b2GPI twice
at least 12 weeks apart [1]. The double testing contri-
butes to the exclusion of patients with a transient reac-
tivity by direct antiphospholipid-antibodies due to
infections or other contributory factors [2,38]. “Lupus
anticoagulant” is a misnomer for a group of various
phospholipid inhibitors, observed usually without under-
lying SLE and in vivo related not to bleeding but to
thrombotic complications. Coagulation tests used to
reveal lupus anticoagulant include: activated partial
thromboplastin time (aPTT), diluted Russell’sv i p e r
venom test (dRVVT), taipan venom test, textarin
venom/ecarin venom clotting time ratio, kaolin clotting
time and tissue thromboplastin inhibition test [38]. Gen-
erally, tests are sensitive but usually need a meticulous
interpretation. For example, a prolongation of clotting
tests such as aPTT, usually is an indication of a bleeding
tendency, but in APLS patients is correlated with a high
risk for thrombotic/thromboembolic events [2,39]. Espe-
cially, some tests such as prothrombin time (PT), aPTT,
or dRVVT based on both calcium and phospholipids
adequacy for further activation of several clotting factors
(Factor II, VII, IX, X) [40]. If the measured time of clot
forming after addition of Ca2+ and PL
(-) is prolonged, a
possible explanation is the existence of antibodies inter-
acting with phospholipids. If the clotting time is not
corrected by addition of normal plasma (mixing step -
corrects missing coagulation factors) but tends to be
normal by adding an excessive amount of phospholipids
(confirmation step by adding activated thrombocytes)
the LA effect is considered “positive” [2,29]. However,
LA testing presents several drawbacks:
a. LA test, considered highly sensitive but not very
specific concerning thromboembolic risk in APLS
patients, can only be reliable if potential sources for
phospholipids are removed before testing. In daily rou-
tine plasma for clotting tests is prepared by centrifuga-
tion of a blood sample, removing red and white blood
cells. However, the smaller and lighter thrombocytes
stay mainly in the supernatant providing a rich source
of PL
(-) [2,38].
b. The prothrombin time is a routine test depending
on Ca2+ and PL
(-) in factor VII, X and II [29]. The acti-
vator, tissue thromboplastin, is extracted from animal
tissues bounding in PL
(-) , rendering this test useless for
APLS diagnosis. Recently a modified test with an exact
amount of recombinant TF and synthetic phospholipids
[2,38] is available allowing the detection of LA.
c. aPTT test may differ because of different ingredi-
ents concerning its sensitivity towards the LA effect.
Especially, the activator (e.g. kaolin, silica, ellagic acid or
celite), the phospholipid source (several animal or plant
sources) and finally the clot-detection method/instru-
ments (photo-optical, mechanical, manual) can vary
widely, influencing the test result [2,40]. Similar to
aPTT is the principle of the dRVVT. At least, both
these tests should always be performed when plasma is
tested for an LA-effect [1]. Anti-cardiolipin test, the
classic solid phase assay test, should be considered only
as a differential diagnosis in a positive test result,
because direct antibodies to CL are not pathogenic for
APLS. One of test limitations, is that both patient’s
serum and buffer solution (usually bovine serum) pro-
vide homologous b2GPI, introducing an extra amount
of target antigens [41]. Therefore, the test result can be
influenced in case of a present human autoantibody
(especially isotype IgM) that reacts exclusively with
human b2GPI [2,41]. Fact that makes the colour reac-
tion less powerful and false-negative as the strength of
reaction is significant for APLS diagnosis; consequently
only moderate to high titer antibodies are considered as
“positive aCL” for APLS [1,2]. Moreover, as mentioned
already for the LA-tests the plasma should be platelet
depleted; otherwise exposed PL
(-) on the surface of acti-
vated platelets attract b2GP. A final pitfall of anti-cardi-
olipin test is that CL represents one of several negatively
charged phospholipids rendering possible to miss a few
cases in which specific autoantibodies react with b2GPI
only when bound to another PL
(-) , e.g. phosphatidylser-
ine [2]. Finally, anti-b2GPI and anti-prothrombin ELISA
tests promise a more specific diagnosis of APLS. Beyond
anti-b2GPI, ELISA tests for antiPT, with prothrombin
directly fixed on a plate or via phosphatidylserine
(antiPS-PT) add further information especially if tests
for LA, aCL or anti-b2GPI are persistently negative
[2,42]. It is debating if these tests have to be repeated
for confirmation of the diagnosis APLS because they are
theoretically not influenced by non-pathogenic antibo-
dies, cancer or drugs [2,42].
Relation of aCL with restenosis following
percutaneous coronary interventions (PCI)
in CAD patients
The role of serum aCL levels in natural history and
prognosis of acute coronary syndromes (ACS) is still
undetermined. However, anticardiolipin antibodies have
been found to be associated with arterial and venous
thrombosis [43]. Angioplasty-induced arterial injury
leads to platelet aggregation, adhesion, and thrombosis.
Several factors that are involved in the thrombogenesis
may influence the restenosis rate after PTCA as throm-
bosis is one of the possible mechanisms of restenosis.
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levels and restenosis after PCI [6]. Contradictory results
have been demonstrated concerning the effect of aCL
antibodies on restenosis. Eber, et al [44] showed that
aCL-IgM was an independent risk factor for restenosis
after PTCA in 65 men with coronary artery disease,
however, no correlation was found between aCL-IgG
and restenosis. Ludia, et al [45] reported that restenosis
was more frequent in aCL positive patients with
ischemic heart disease. Gurlek et al [6] studied the fol-
low-up coronary angiography in two groups of 80
patients with acute coronary syndrome, in comparison
to IgM and IgG aCL levels measured before hospital dis-
charge. The results suggested that restenosis occurs
more frequently in anticardiolipin positive patients. In
contrast, Chiarugi, et al [46] observed no association
between the presence of aCL and clinical restenosis,
however, the presence of aCL with elevated lipoprotein
a [Lp(a)] levels, acting synergistically, increased the risk
of restenosis. Finally, in a recent study, Sharma S et al
[47], failed to demonstrate any significant correlation
between the level of IgG anticardiolipin antibodies and
in-stent restenosis in patients having undergone PCI
with bare metal or drug eluting stents. The corellation
of elevated aCL levels and post-ACS cardiovascular
events is still controversial. The largest study on this
issue was recently reported by Bili et al, [48] who stu-
died 1150 AMI patients, demonstrating that elevated
aCL-IgG and low aCL-IgM antibodies were independent
risk factors for recurrent cardiovascular events. Zucker-
man et al, [49] suggested that the presence of aCL is a
marker for increased risk for myocardial reinfarction
and thromboembolic events after acute myocardial
infarction (MI). However, Hamsten and colleagues [50]
demonstrated that antibodies to cardiolipin are markers
for a high risk of recurrent cardiovascular events in
young survivors of MI; but their study was small in
scope. On the contrary, Sletnes, et al [51] in 597 acute
MI survivors, using multivariate analysis, failed to prove
that aCL is an independent risk for mortality, cerebral
thromboembolism, or recurrent MI. Analogous results
were obtained by Cortellaro et al, [52] in their study of
74 young MI patients and Phadke et al, [53] who mea-
sured aCL in 299 survivors of acute MI. Eventually,
Gurlek et al, [6] found no association between aCL anti-
bodies with recurrent cardiovascular events (reinfarction
and intracardiac thrombus formation) in ACS patients.
Intraoperative management of coagulation:
a crucial problem
Patients with APLS are at increased risk for thrombosis
and adequate anticoagulation is of vital importance dur-
ing cardiopulmonary bypass (CPB) [18,30,31,54,55]. Peri-
operative risks include thrombosis and/or bleeding
secondary to excessive anticoagulation or APLS asso-
ciated clotting factor deficiencies (especially factor II)
[18]. In the meantime, minor alterations in anticoagulant
therapy, infection, or a surgical insult may trigger wide-
spread thrombosis. Moreover, deep hypothermic circula-
tory arrest (DHCA) complicates the problem of
anticoagulation during cardiac surgery because of the
combination of blood stasis and changes in enzymatic
activity associated with the extreme temperature differ-
ences [56,57]. Therefore, the management of anticoagula-
tion during CPB can be quite challenging and close
cooperation with the haematology department is essen-
tial. There is no consensus in the literature as to the opti-
mal method for assuring perioperative anticoagulation in
APLS. While, monitoring anticoagulation in APLS
patient during cardiac surgery remains problematic, as
aPL often interfere with in vitro tests of hemostasis by
impeding the binding of coagulation proteins to phos-
pholipid surfaces [21]. Especially, during CPB, blood con-
tact with extracorporeal surfaces causes stimulation of
the coagulation cascade. To prevent clotting, unfractio-
nated heparin is administered before CPB. Heparin con-
centrations of greater than/equal to 3 u/ml ± 1 are
generally accepted as therapeutic for CPB [58], but indi-
vidual patient responses to a standardized heparin dose
vary. Heparin activity is assessed using the activated clot-
ting time (ACT) which is a phospholipid dependent test
and may be prolonged by LA antibodies [18]. In the nor-
mal patient, a heparin concentration of 3 uml ± 1 typi-
cally produces a kaolin ACT of more than 450 seconds.
LMWH is attractive in this setting as it causes a highly
predictable anticoagulant effect for a given dose, decreas-
ing the need for monitoring [18]. Suggested alternative
methods for monitoring anticoagulation during bypass in
APLS patients include empirically doubling the baseline
ACT or to reach an ACT twice the upper limit of normal
[2], obtaining heparin concentrations by protamine titra-
tion (Hepcon) [59], performing anti-factor Xa assays, or
performing heparin/ACT titration curves preoperatively
to determine patient specific target ACT levels [18]. The
in vitro heparin/ACT titration curve is a test of an indivi-
dual patient’s responsiveness to heparin. Moreover, preo-
peratively, anti-Xa factor activity assays can be correlated
with the patient specific preoperative in vitro heparin
ACT titration curve [18]. Anti-Xa monitoring is generally
considered the"gold standard” laboratory measure of
heparin therapy for use in situations in which the aPTT
may be adversely affected [22]. By using this testing
method, known concentrations of purified coagulation
factor Xa and antithrombin are mixed with a sample of
the patient’s heparin-containing plasma [18,22]. Anti-fac-
tor Xa levels of 1.5 ± 2.0 u/ml ± 1 are considered thera-
peutic for CPB [18]. Postoperatively, levels greater than
1.0 u/ml ± 1 may be associated with excess blood loss
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However, the turnaround time for anti-factor Xa assays
are currently incompatible with the time constraints of
CPB [18,60]. Generally, various anticoagulation methods
for dosing heparine during CPB have been performed.
Especially, Sheikh et al [61] elected to empirically double
the ACT to more than 999 seconds; as obtaining factor
Xa or plasma heparin concentrations was considered
impractical. On the other hand, East et al [22] elected to
perform heparin-celite ACT titration curves preopera-
tively on each patient to assess the effect of APL antibo-
dies on ACT monitoring. Based on the patient-specific
titration curve, therapeutic anticoagulation (heparin con-
centration 3.0 U/mL) for CPB was achieved in patients at
celite ACT values exceeding 550 s. Also, laboratory based
anti-Xa monitoring was performed concurrently during
CPB as a secondary confirmatory measure [22]. In retro-
spective studies, a lower incidence of recurrences (arterial
and venous) episodes of thrombosis was observed in
patients kept at a high intensity of oral anticoagulation
[62-64] leading to the recommendation that patients with
antiphospholipid antibodies who have had a documented
major thrombotic event should receive life-long oral
anticoagulant treatment to achieve an INR of 3.0 or
higher [62,65,66]. In spite of anticoagulant treatment,
recurrence of thrombosis is frequent in patients with the
APLS [63,67], especially in those carrying lupus anticoa-
gulant (LA) [68] and/or high titers of anticardiolipin anti-
bodies [63,67]. Especially, Della Valle et al [63] showed
that INR determinations obtained with a recombinant PT
reagent substantially overestimate the actual degree of
anticoagulation of most lupus anticoagulants patients
due to interference of lupus anticoagulant IgG in PT
assays carried out at low test plasma dilution, as occurs
with plain and recombinant thromboplastin reagents.
Also, according to the Duration of Anticoagulation Study
Group, patients with anti-cardiolipin IgG antibodies
require prolonged anticoagulation to avoid recurrences
of venous thromboembolism [69]. In addition, while on
oral anticoagulant treatment targeted at an INR between
2.0 and 2.85, the recurrence rate increased with the antic-
ardiolipin antibody titter, but was not significantly differ-
ent in patients with (1.32 per 100 patient-years) or
without (0.6 per 100 patient-years) anti-cardiolipin anti-
bodies [69]. Specifically, patients with primary APLS with
thrombosis are treated with heparin followed by warfarin
in the usual manner [18]. There is controversy over the
intensity of anticoagulant therapy, the duration of treat-
ment, and the method for measuring the INR. Recurrent
thrombotic events of any type usually signal the need for
life-long anticoagulation. Recurrent thrombosis while on
standard intensity anticoagulant therapy dictates the use
of a higher target INR at about 2,5-3,5 [70], but the INR
may not correlate well with diagnosis or outcome in
APLS [71]. Although the risk of thrombosis is reduced
with increased anticoagulation, there is an associated
increased risk of significant bleeding [18]. Protamine to
antagonise heparin should be administered only in a
stepwise manner or in low dose continuously intrave-
nous, e.g. 50 mg/h [2], until the bleeding tendency slows
down to an acceptable amount. Also, a scrutinised opera-
tive technique and haemostasis to avoid any unnecessary
surgical bleeding site are of great importance [2]. In
patients with secondary APLS and thrombosis, there is
an ongoing endothelial disturbance secondary to the
underlying vasculitis and the risk of recurrent thrombotic
events is high [2]. Anti-platelet therapy as well as war-
farin anticoagulation is indicated. Moreover, additional
factors of thrombosis such as hypertension, diabetes mel-
litus, hyperlipidaemia should be treated optimally or
avoided (e.g. smoking) [2]. Generally, antiplatelet therapy
may be added but the effectiveness of low-dose aspirin or
the newer antiplatelet agents is unproven. In cases where
thrombosis continues despite adequate anticoagulation,
additional treatment is aimed either at preventing anti-
body formation or reducing antibody titres and may
include corticosteroids, immunosuppressive agents, i.v.
immuneglobulin, or plasmapheresis. Particularly, Dor-
man R [18] described the perioperative course and suc-
cessful treatment of a 31-yr-old woman with primary
APLS requiring a mitral valve replacement; that post-
operatively, developed acute global biventricular failure
requiring extracorporeal membrane oxygenation support
and plasmapheresis. Alternative methods for anticoagula-
tion during CPB are essential and multiple options are
available today [56]. These options include ancrod, hiru-
din, lepirudin, argatroban, prostacyclin, platelet IIb/IIIa
inhibitors, complement inhibitors, IL-3 and bivalirudin
[56,72]. Also, tissue plasminogen activator has been used
successfully in one case report of APLS with ST changes
and normal coronary arteries [73]. Bivalirudin is a biva-
lent reversible direct thrombin inhibitor and has been
used safely for CPB in HIT-positive patients [56,72,
74-76]. It is also successfully used during off-pump/
on-pump coronary artery bypass grafting and heart trans-
plantation [77-79]. Bivalirudin is a bivalent direct throm-
bin inhibitor with a short half-life of approximately 25
minutes [56]. Its 20-amino acid molecule combines a car-
boxy-terminal region that recognizes thrombin’sf i b r i n
(ogen)-binding site, and an amino-terminal tetrapeptide
that inhibits the active site of thrombin [56]. Conse-
quently, thrombin inhibition of bivalirudin inactivates
not only fluid-phase thrombin, but also fibrin-bound
thrombin [80]. Therefore, thrombus formation may be
attenuated more effectively and anticoagulation produced
more predictably than by heparin [56,80]. Pharmaco-
kinetically bivalirudin is predominantly eliminated by
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i t s e l f( 8 0 % )a n dt oal e s s e rd e g r e eb yr e n a lc l e a r a n c e
(20%) [81]. No reversal for bivalirudin exists, but its elim-
ination can be enhanced by hemodialysis and hemofiltra-
tion [81,82]. The theoretical potential of aprotinin to
delay bivalirudin elimination and to prolong its anticoa-
gulant effect has not been demonstrated [56]. In one
study aprotinin did not affect the elimination of bivaliru-
din [82]. Leissner et al [56], reported a case from a
patient with APLS with massive thrombosis of right
atrium. This patient underwent DHCA by using bivaliru-
din, for thrombectomy to avoid potential catastrophic
pulmonary embolism. During CPB the ACT was restored
between 500-750 sec with the initial dose of bivalirudin
and during the circulatory arrest the arterial and venous
lines were clamped and the CPB circuit was recirculated
distal to the arterial filter back to the soft-shelled venous
reservoir to avoid pump clotting [56]. The DHCA time
was planned to be short and lasted 19 minutes. No visible
clot formation was observed in the open-heart and
bypass circuit, but in the pericardial cavity as previously
attributed to increased blood stagnation [72,79]. cAPLS
is caused by a generalised thrombotic storm due to
excessive activation of “aPL” with consecutive multi
organ failure and peripheral ischaemic lesions as digital
necrosis [2]. Also, acute single organ failure (e.g. acute
heart failure) representing complications of APLS should
be treated similar to cAPLS. The baseline is an aggressive
intravenous anticoagulation, usually heparin, later fol-
lowed by oral anticoagulation with vitamin K-antagonists
[2,83]. Steroids may contribute to limitation of the cyto-
kine release and further treat the widespread vasculitis
[83]. Moreover, plasmapheresis or intravenous gamma-
globulins reduce the autoantibody load, improving the
outcome [2,84]. The use of prostacyclin, fibrinolytics,
cytotoxic drugs, splenectomy or dialysis are described but
without proven advantage for survival. In Asherson and
colleagues [83] most recent retrospective case series of
cAPLS, only anticoagulation was associated with statisti-
cally significant increased survival. While, in previous
Asherson and colleagues series [84], plasmapheresis did
reduce mortality. Also, there are case reports of acute
biventricular failure in APLS with necropsy findings of
myocardial microvascular thrombosis [85-89]. In this
situation, antithrombotic not anti-inflammatory therapy
is likely to be effective [18]. A diagnosis of fulminant
myocarditis could be supported by the global nature of
the myocardial dysfunction and its prompt resolution.
Fulminant myocarditis is associated with full recovery in
over 90% of the patients who survive the event [89].
There is one case report of APLS associated postopera-
tive fulminant myocarditis managed with immunosup-
pressive steroids [90]. Currently, there is some scientific
rationale for adding a statin as adjunctive treatment.
Statins may be beneficial in APLS patients by suppressing
the inflammatory response, which is important in case of
valvular lesions and vascular occlusive disease [8]. How-
ever, no clinical investigations using statins as anti-
inflammatory treatment in APLS patients have been
reported. Finally, specific therapeutic treatment for APLS
is not available yet. The application of peptides specifi-
cally bound by anti-b2GPI antibodies thus neutralising
the functional effect of the autoantibodies [91] or pep-
tides which have a similar amino acid sequence as
domain V of b2GPI thus possibly blocking putative
receptors in an antagonistic manner [2,92] constitute
promising therapeutic approaches.
Outcomes of cardiac surgery in APLS patients
The literature offers widely differing estimates of mor-
bidity and mortality associated with APLS and cardio-
pulmonary bypass. In a retrospective analysis of 19
patients with APLS undergoing cardiac or vascular sur-
gical procedures, Ciocca and colleagues reported an
84.2% incidence of postoperative thrombosis or bleeding
and 63.2% mortality [31]. Thirteen of the patients in
these series underwent cardiac surgery. Individual case
reports of cardiac surgical patients frequently describe
thrombotic or haemorrhagic complications including
early graft occlusion [93] haemothorax [94], pulmonary
emboli, and limb ischaemia [95,96]. More optimistically,
the literature includes several case reports of uneventful
cardiac surgery [97,98]. A meta analysis of heart valve
surgery by Gorki et al [2] demonstrated that the mortal-
ity is high with 7% early deaths and 12% late deaths
after a mean follow-up period of less then 3 years. The
early and late morbidity with major complications (valve
related included) respectively is significant. Only 42% of
the patients had an uneventful short and long-term
recovery. APLS-typical processes could be explanation
for the majority of postoperative problems, especially for
myocardial and cerebral complications and other overt
thromboembolic events. The high proportion (about
20%) of valve-related complications such as valve throm-
bosis is remarkable. Colli et al [99], in a recent retro-
spective analysis of nine patients with antiphospholipid
syndrome that underwent heart valve surgery using
CPB, observed high morbidity (50%) and mortality
(22%) respectively. Especially, two patients died in the
early postoperative period due to an acute cerebrovascu-
lar accident, four patients presented an uneventful late
postoperative course and one patient experienced an
ischemic stroke 5 years after mitral valve replacement
and developed refractory congestive heart failure requir-
ing heart transplantation three years postoperatively.
Similarly, Berkun et al [55] presented an increased mor-
bidity and mortality in ten patients with APLS under-
going valve replacement.
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APLS is one of the most commonly acquired hypercoa-
gulable states. Minor alterations in the anticoagulation,
infection, and surgical insult may trigger widespread
thrombosis. The incidence of thrombosis is highest dur-
ing the following perioperative periods: preoperatively
during the withdrawal of warfarin, postoperatively dur-
ing the period of hypercoagulability despite warfarin or
heparin therapy, or postoperatively before re-establishing
adequate anticoagulation. The resources to manage
major complications are essential. A successful outcome
requires multidisciplinary management in order to pre-
vent thrombotic or bleeding complications and to man-
age perioperative anticoagulation. More work and
reporting on anticoagulation management and adjuvant
therapy in patients with APLS during extracorporeal cir-
culation are necessary.
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